Seaport Therapeutics, Inc. balance sheet SPTX

As of Sep 30, 2026, Seaport Therapeutics, Inc. had total assets of $417.6 million and total liabilities of $20.2 million. Stockholders' equity was $397.5 million. It held $403.8 million in cash and investments against $4.7 million of total debt, net cash of $399.1 million. The current ratio, current assets divided by current liabilities, was 17.48.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Assets
Cash
62
64
53
Short-term investments
229
209
130
Long-term investments
113
154
30
Cash and investments
404
427
213
Total current assets
299
282
188
Property and equipment, net
0
0
0
Total assets
418
442
228
Liabilities and equity
Accounts payable
6
6
5
Total current liabilities
17
16
14
Total liabilities
20
19
18
Stockholders' equity
397
423
-116
Debt
Lease liabilities
5
5
5
Total debt
5
5
5
Net cash
399
422
207
Ratios
Current ratio
17.48x
18.00x
13.24x
Debt to equity
0.01x
0.01x
—
Book value per share
7.42
7.89
-44.55
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SPTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2042347

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.